New genetic test now available for warfarin

June 11, 2007

The Warfarin DoseAdvise Genetic Test has been launched by Kimball Genetics. It can detect the presence of variations in the CYP2C9 and VKORC1 genes, both of which decrease the warfarin dose requirement.

The Warfarin DoseAdvise Genetic Test has been launched by Kimball Genetics. It can detect the presence of variations in the CYP2C9 and VKORC1 genes, both of which decrease the warfarin dose requirement. The company offers a one-day turnaround time along with detailed reports with interpretation of the results and dosing recommendations. According to the company, the test can be performed on buccal cells as a convenient alternative to blood and is accurate 99.9% of the time for either sample type. The new test may also help shorten the time to achieve therapeutic dosing and reduce the number of dosage adjustments necessary.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.